HTA Details
Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions
- Publication date
-
2020-November-02
- Status
- Final
- Topic Area
- Skin
- Recommendation
-
Final Recommendation
- Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends publicly funding home narrowband ultraviolet B (UVB) phototherapy as an option for people with photoresponsive skin conditions that require treatment with narrowband UVB phototherapy
- Ministry Response
-
The Ministry of Health is currently reviewing this recommendation.
-
Some skin conditions can be treated with ultraviolet radiation, which is a type of light that’s not visible. These are defined as photoresponsive skin conditions – the most commonly treated are psoriasis, vitiligo, eczema, and cutaneous T-cell lymphoma (a type of skin cancer). This type of treatment does not cure the condition; often treatment needs to be continued or symptoms may return.
Narrowband ultraviolet B phototherapy is the most common type of therapy for these conditions. It involves exposing the affected person to ultraviolet radiation. Treatment is usually done in an outpatient setting, such as a clinic or doctor’s office. However, people who have difficulty getting to a clinic may benefit from narrowband ultraviolet B phototherapy in their home.
This health technology assessment looked at how safe, effective, and cost-effective home narrowband ultraviolet B phototherapy is for people with some photoresponsive skin conditions. It looked at the budget impact of publicly funding home narrowband ultraviolet B phototherapy. It also looked at the experiences, preferences, and values of people with photoresponsive skin conditions.
Last Updated: February 24, 2026